We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Horiba Presents Comprehensive Range of Hematology, Hemostasis and Clinical Chemistry Analyzers at MEDLAB Middle East

By LabMedica International staff writers
Posted on 24 Jan 2022

Image: Horiba at MEDLAB Middle East 2022 (Photo courtesy of Horiba Medical)

Image: Horiba at MEDLAB Middle East 2022 (Photo courtesy of Horiba Medical)

Horiba Medical (Kyoto, Japan) presented its comprehensive hematology, hemostasis and clinical chemistry analyzer ranges, as well as its HELO Solution that meets all laboratory configuration needs at MEDLAB Middle East 2022.

At the 2022 edition of MEDLAB Middle East, Horiba displayed its Yumizen G Range of five hemostasis analyzers and a comprehensive reagents menu from routine to specialized tests. Also on display was Horiba’s new compact hematology system the Yumizen H550 that provides full walk-away capability to small-mid size laboratories. The Yumizen H550 is a compact hematology system with integrated sample rack auto loading that is designed to provide rapid testing and full hematology diagnosis. It provides the operator with a full walk-away capacity of 40 tubes with continuous loading. Based on proven and innovative technologies, it answers the need for a robust analyzer and requires no user maintenance. Horiba also displayed the Yumizen H2500, its new generation automated hematology analyzer that answers customers expectations of solid and reliable diagnostic technology as well as rapid and consistent results.

The focus at Horiba’s demonstrations at the event was on the company’s global hematology solution, the HELO Solution (HORIBA Evolutive Laboratory Organization). HELO is an innovative design solution covering all the needs of a high throughput automated hematology platform. Flexible and efficient, HELO is the optimum answer to the constant evolution of any laboratory. The HORIBA advanced technologies embedded in the Yumizen H2500/H1500 associated with over 30 years experience in Hematology diagnosis offer the highest analytical performances. Thanks to its data, tube management, waste, blood film and digitalization management capability, HELO not only addresses a lab’s needs, but helps them to optimize TAT, floor space and reagent storage.

Related Links:
Horiba Medical

Visit expo >

New

Gold Member

Pre- Eclampsia Control

Acusera Pre-Eclampsia Control

Online QC Software
Acusera 24•7

Automatic CLIA Analyzer

Shine i6000

Automated Urinalysis Solution

UN-9000

Latest Medlab 2022 News

Channels

Clinical Chemistry

view channel

FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis

Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more

Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes

Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read more

Blood Test Detects More High-Risk Prostate Cancers Than PSA

Prostate cancer is one of the most common malignancies in men, and screening often struggles to distinguish indolent tumors from clinically significant disease. Prostate-specific antigen (PSA) testing... Read more

Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke

Rapid and accurate differentiation of stroke types remains a persistent challenge in emergency medicine, particularly because early imaging can miss ischemic events that require time-sensitive intervention.... Read more

Molecular Diagnostics

view channel

Image: New findings show that the transcription factor IRF2 has both pathogenic and prognostic significance in multiple myeloma (Image Credit: Shutterstock)

New Molecular Marker Helps Predict Multiple Myeloma Prognosis

Multiple myeloma is a bone marrow cancer marked by resistance to therapy and frequent relapse, complicating long-term disease control. Better molecular markers are needed to refine risk assessment and... Read more

Blood-Based RNA Biomarker Improves Prediction of Alzheimer’s Onset

Timely identification of patients approaching symptomatic Alzheimer’s disease (AD) remains a major clinical challenge, even as blood-based biomarkers continue to advance. Current assays are highly effective... Read more

Multiplex PCR Test Identifies Seven STI Pathogens in One Hour

Sexually transmitted infections (STIs) continue to rise, increasing demand for rapid, accurate detection of multiple pathogens across varied sample types. To support flexible, standardized testing, a new... Read more

Gene Expression Test Supports Metastatic Risk Assessment in Melanoma

Accurate metastatic risk assessment in early-stage cutaneous melanoma is essential for guiding sentinel lymph node biopsy and follow-up decisions, particularly in patients with stage IB tumors such as... Read more

Hematology

view channel

Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows

Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more

Image: Direct and indirect antitumoral effects of eosinophil (Marie Gilon et al., Journal of Experimental & Clinical Cancer Research (2026). DOI: 10.1186/s13046-026-03688-5)

Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity

Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more

Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children

Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more

Image: Graphical abstract (Waclawiczek A, Leppä AM, Renders S, et al. Cell Stem Cell, 2026. doi:10.1016/j.stem.2026.04.012)

Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more

Immunology

view channel

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more

Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV

Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more

Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission

Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read more

New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease

Autoimmune disorders arise when immune responses target self-antigens, driving chronic inflammation and long-term morbidity. In primary Sjögren disease, inflammation of salivary and lacrimal glands leads... Read more

Microbiology

view channel

Rapid Gastrointestinal PCR Panels Deliver One-Hour Results

Acute infectious gastroenteritis remains a major cause of illness worldwide, especially in young children, older adults, and immunocompromised patients. Nonspecific symptoms such as diarrhea, vomiting,... Read more

H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention

Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more

Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer

Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read more

Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella

Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more

Pathology

view channel

AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers

Immunotherapy has transformed care for select malignancies, yet predicting which patients with rare cancers are most likely to benefit remains challenging. Clinicians often have only limited biomarkers... Read more

Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping

Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more

Study Highlights Biomarker Testing Delays in Lung Cancer Care

Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read more

Stain-Free Imaging Platform Matches Standard Cancer Pathology

Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more

Technology

view channel

AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines

Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more

Agentic AI Platform Supports Genomic Decision-Making in Oncology

Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more

Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps

Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more

Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance

Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read more

Industry

view channel

Partnership Integrates Automated DNA Extraction with Single-Molecule Digital PCR

Countable Labs (Palo Alto, CA, USA) and Promega (Madison, WI, USA) have entered a co-marketing agreement that integrates the Promega Maxwell System for nucleic acid extraction with Countable Labs’ Countable... Read more

Agilent Strengthens Pathology Capabilities Through Biocare Acquisition

Agilent Technologies has completed its acquisition of Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners LLP. Biocare is now part of Agilent’s Life Sciences and Diagnostics... Read more

Merck KGaA to Acquire Bio-Techne, Expanding Life Science Portfolio

Merck KGaA (Darmstadt, Germany) agreed on June 25, 2026, to acquire Bio-Techne Corporation (Minneapolis, MN, USA) for US$73 per share in cash, valuing the transaction at approximately US$11.... Read more

Project Aims to Develop First Single-Cell Assay for ADC Therapies

Antibody-drug conjugates are expanding rapidly in oncology, intensifying the need for biomarker strategies that capture tumor heterogeneity at cellular resolution. Single-cell profiling can delineate cellular... Read more